Automated Imaging Differentiation of Parkinsonism

Key facts

Sponsor

University of Florida

Intervention

AIDP(diagnostic_test)

Enrollment

315 enrolled

Eligibility

40-80 years · All sexes

Timeline

2021 – 2026

Study locations (21)

• University of Alabama at Birmingham, Birmingham, Alabama, United States
• University of California San Diego, La Jolla, California, United States
• University of California San Francisco, San Francisco, California, United States
• University of Florida, Gainesville, Florida, United States
• University of South Florida, Tampa, Florida, United States
• Augusta University, Augusta, Georgia, United States
• Northwestern University, Chicago, Illinois, United States
• University of Chicago, Chicago, Illinois, United States
• University of Kentucky, Lexington, Kentucky, United States
• Johns Hopkins University, Lutherville, Maryland, United States
• Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
• Massachusetts General Hospital, Charlestown, Massachusetts, United States
• University of Michigan, Ann Arbor, Michigan, United States
• University of Minnesota, Minneapolis, Minnesota, United States
• Washington University in St. Louis, St Louis, Missouri, United States
• +6 more locations on ClinicalTrials.gov

Collaborators

Augusta University · Albany Medical College · Beth Israel Deaconess Medical Center · Duke University · Johns Hopkins University · Massachusetts General Hospital · Northwestern University · Ottawa Hospital Research Institute · Penn State University · University of Alabama at Birmingham · University of California, San Diego · University of California, San Francisco · University of Chicago · University of Michigan · University of Minnesota · University of South Florida · Centre for Addiction and Mental Health · Wake Forest University · Washington University School of Medicine · University of Kentucky · National Institute of Neurological Disorders and Stroke (NINDS)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Classic progressive supranuclear palsy syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07509125
  Ultra-High Resolution PET in Aging, Neurodegeneration and Psychotic Disorders
  Universitaire Ziekenhuizen KU Leuven
• RECRUITINGEARLY PHASE1NCT07348276
  First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain
  Invicro
• RECRUITINGNANCT07291687
  tDCS as Treatment for Motor Function
  Baycrest
• ACTIVE NOT RECRUITINGNANCT06588673
  Art Therapy in Progressive Supranuclear Palsy
  Vanderbilt University Medical Center
• ENROLLING BY INVITATIONNANCT06597071
  Parkinson Atypical Rating of Oculometric Patterns Evaluated Routinely
  NeuraLight
• ACTIVE NOT RECRUITINGPHASE2NCT06355531
  A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
  Ferrer Internacional S.A.
• RECRUITINGNCT06949865
  AI-Enhanced Optimization of Acute Levodopa Challenge Test
  Beijing Tiantan Hospital
• RECRUITINGNANCT06174948
  The Use of the CUE1/CUE1+ in People With Parkinson's Disease and Related Disorders
  Queen Mary University of London

See all trials for Classic progressive supranuclear palsy syndrome →